Asim Amin, MD
Medical Oncology · Washington, DCNPI 1518965607
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (59.9%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 12 manufacturers reported payments, led by E.r. Squibb & Sons, L.L.C. at 39.2% of the total. Reporting peaked in 2019 at $55,144 and has fallen 94.3% since, to $3,166 in 2025.
Across 115 payments — averaging $1042.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$47K
- Merck$16K
- Sanofi$13K
- Regeneron Healthcare Solutions, Inc.$12K
- Novartis$10K
- Eisai Inc.$8K
- plus $15K from 6 others
Across 246 payments — averaging $21,449 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- E.r. Squibb & Sons, L.L.C.$3.1M
- Merck$1.6M
- Dynavax Technologies Corporation$320K
- Exelixis Inc.$171K
- Regeneron$111K
What the payments were for
- Consulting fees$34,68929%
- Speaking & faculty fees$71,81660%
- Travel & lodging$10,0498%
- Food & beverage$3,2983%
- Education$370%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 34 | $46,967 |
| Merck | 18 | $15,717 |
| Sanofi | 7 | $13,310 |
| Regeneron Healthcare Solutions, Inc. | 17 | $11,585 |
| Novartis | 9 | $10,005 |
| Eisai Inc. | 6 | $7,525 |
| Exelixis Inc. | 15 | $7,230 |
| Array Biopharma Inc | 3 | $3,976 |
| Bristol Myers Squibb | 3 | $3,300 |
| Clinigen, Inc. | 1 | $157 |
| Regeneron | 1 | $102 |
| Genentech USA, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$119,887 in reported general payments places this provider in the 80th percentile of 29 medical oncology providers in District of Columbia.
See all medical oncology providers in District of Columbia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LenvimaLenvatinib Mesylate | 79 | $1,873,611 |
| BraftoviEncorafenib | 43 | $666,658 |
| MektoviBinimetinib | 43 | $510,538 |
| WeliregBelzutifan | 17 | $458,921 |
| Everolimus | 29 | $104,101 |
| EliquisApixaban | 24 | $11,199 |
| Budesonide DrBudesonide | 20 | $1,676 |
| Levothyroxine Sodium | 104 | $938 |
| Dexamethasone | 23 | $371 |
| Triamcinolone Acetonide | 21 | $337 |
| Pantoprazole Sodium | 30 | $321 |
| Prednisone | 80 | $274 |
| Famotidine | 22 | $134 |
| Gabapentin | 16 | $127 |
| Ondansetron Hcl | 12 | $59 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Eisai Inc.Lenvima | $7,525 | $1,873,61179 claims |
| Array Biopharma IncBraftovi, Mektovi | $3,976 | $1,177,19686 claims |
| MerckWelireg | $15,717 | $458,92117 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 29 medical oncology providers in District of Columbia.
Other medical oncology in Washington
- Nancy DawsonWashington$1.7M
- Joshua ReussWashington$218K
- Pashna MunshiWashington$189K
- Michael PishvaianWashington$147K
- Kieron DunleavyWashington$139K
- Mitchell SmithWashington$41K
- Channing PallerWashington$33K
- Solmaz SahebjamWashington$31K
- Khaled El-ShamiWashington$27K
- Kimberley DoucetteWashington$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.